Condition
B-cell Non-Hodgkins Lymphoma (B-NHL)
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (3)
Trial Status
Recruiting2
Withdrawn1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05685173Phase 1RecruitingPrimary
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
NCT07205315Early Phase 1Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
NCT07334574Phase 1Not Yet RecruitingPrimary
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
NCT05513612Phase 1Withdrawn
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Showing all 4 trials